ASCO 2025 – Enhertu mounts its first-line charge
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
ASCO 2025 – Amgen gets one over on Zai Lab
Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.
ASCO 2025 – Astellas's new Claudin18.2 interest
Evopoint reveals intriguing but opaque first-in-human data for XNW27011.
ASCO 2025 – Lilly makes a folate foray against Genmab
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
ASCO 2025 – Astra "looked at" patritumab but passed
As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.
ASCO 2025 – Astra seeks a new SERD paradigm
But camizestrant’s use could depend on uptake of monitoring – for now.
ASCO 2025 – J&J takes another prostate cancer shot
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
